Top Stories Analysts Set Target Price for BridgeBio Pharma at $79.05 Financial analysts have established a target price of $79.05 for BridgeBio Pharma, Inc. (NASDAQ: BBIO), indicating a generally positive outlook for the biopharmaceutical company.... Editorial17 February, 2026
Business BridgeBio Pharma Hits New 52-Week High as Analysts Boost Ratings Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) reached a new 52-week high of $78.47 during trading on Friday, October 30, 2023. The stock closed at... Editorial2 January, 2026